|

Sacituzumab govitecan Clinical Trials

36 actively recruiting trials across 15 locations

▲ +2 trials since May 2026

Also known as: GS-0132, IMMU 132, IMMU-132, IMMU132, RO7445735 +10 more

Pipeline

Phase 1: 2Phase 2: 24Phase 3: 5Phase 1/2: 4

Top Sponsors

  • National Cancer Institute (NCI)4
  • Dana-Farber Cancer Institute3
  • M.D. Anderson Cancer Center2
  • H. Lee Moffitt Cancer Center and Research Institute2
  • Yale University1

Indications

Other15 trials

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer
Phase 2
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
Phase 2
HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan
Phase 2
Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Phase 2
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
Phase 3
Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer
Phase 2
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
Phase 2
Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer
Phase 1/2
Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma
Phase 2
Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)
Phase 2
Sacituzumab govitEcan in THYroid Cancers
Phase 2
Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer
Phase 3
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
Phase 3
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
Phase 3

Boston, Massachusetts3 trials

Sacituzumab Govitecan In TNBC

Beth Israel Deaconess Medical Center

Phase 2
Scalp Cooling in MBC

Brigham and Women's Hospital

Phase 2
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Dana-Farber Cancer Institute

Phase 1

Duarte, California2 trials

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope

Phase 1/2
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

City of Hope Comprehensive Cancer Center

Phase 2

Tampa, Florida2 trials

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Moffitt Cancer Center

Phase 1/2
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Moffitt Cancer Center

Phase 2

Cleveland, Ohio2 trials

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Phase 1
Sacituzumab Govitecan in Recurrent Glioblastoma

Cleveland Clinic Taussig Cancer Center

Phase 2

Houston, Texas2 trials

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

M D Anderson Cancer Center

Phase 2
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

The University of Texas M. D. Anderson Cancer Center

Phase 1/2

Phoenix, Arizona1 trial

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Cancer Center at Saint Joseph's

Phase 3

Los Angeles, California1 trial

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

UCLA Jonsson Comprehensive Cancer Center

Phase 2

Orange, California1 trial

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

UC Irvine Health/Chao Family Comprehensive Cancer Center

Phase 2

San Francisco, California1 trial

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

University of California San Francisco

Phase 2

New Haven, Connecticut1 trial

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

Smilow Cancer Hospital at Yale New Haven

Phase 2

Stamford, Connecticut1 trial

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Stamford Hospital

Phase 2

Bethesda, Maryland1 trial

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

National Institutes of Health Clinical Center

Phase 2

Detroit, Michigan1 trial

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Henry Ford Cancer- Detroit

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Phase 2

Nashville, Tennessee1 trial

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

Vanderbilt University/Ingram Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.